Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Review

The emerging role of Nemo-like kinase (NLK) in the regulation of cancers

Authors: Ying Huang, Yang Yang, Yong He, Jun Li

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Nemo-like kinase (NLK) is an evolutionarily conserved mitogen-activated protein (MAP) kinase-related kinase that is highly expressed in neural tissues and minimally detected in others. Accumulating evidence demonstrates that NLK exerts a pivotal role in cell proliferation, migration, invasion, and apoptosis via regulation of a variety of transcriptional molecules. The results of recent studies have shown that aberrant expression of NLK is significantly associated with the initiation and progression of various types of human cancers, as well as clinicopathologic features and survival rate. NLK is gradually considered as a potential tumor suppressor or an oncogene depending on the tumor system, and silencing or upregulating of NLK may provide an effective therapeutic approach against tumors. In this review, we will make a summary on the comprehensive roles of NLK in the regulation of various cancers.
Literature
1.
Choi KW. Rotation of photoreceptor clusters in the developing Drosophila eye requires the nemo gene. Cell. 1994;78:125–36.CrossRefPubMed
2.
3.
Katoh M. Comparative genomics on nemo-like kinase gene. Int J Oncol. 2005;26:1715–9.PubMed
4.
Kortenjann M. Abnormal bone marrow stroma in mice deficient for nemo-like kinase Nlk. Eur J Immunol. 2001;31:3580–7.CrossRefPubMed
5.
Ishitani T. Nemo-like kinase is involved in NGF-induced neurite outgrowth via phosphorylating MAP1B and paxillin. J Neurochem. 2009;111:1104–18.CrossRefPubMed
6.
Xu D. Expression of Nemo-like kinase after spinal cord injury in rats. J Mol Neurosci. 2014;52:410–8.CrossRefPubMed
7.
8.
Thorpe CJ. nemo-like kinase is an essential co-activator of Wnt signaling during early zebrafish development. Development. 2004;131:2899–909.CrossRefPubMed
9.
Ishitani T. Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal. 2013;25:190–7.CrossRefPubMed
10.
Jung KH. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 2010;110:687–96.CrossRefPubMed
11.
Li M. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol. 2013;34:3995–4000.CrossRefPubMed
12.
13.
Zhang Y. Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer. 2011;21:1380–7.CrossRefPubMed
14.
15.
Shaw-Hallgren G. Association of nuclear-localized Nemo-like kinase with heat-shock protein 27 inhibits apoptosis in human breast cancer cells. PLoS One. 2014;9:e96506.CrossRefPubMedPubMedCentral
16.
Lv L. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem. 2014;115:81–92.CrossRefPubMed
17.
Cui G. Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 2011;18:271–5.CrossRefPubMed
18.
Han Y. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother. 2014.
19.
Chen J. Nemo-like kinase expression predicts poor survival in colorectal cancer. Mol Med Rep. 2015;11:1181–7.PubMed
20.
Tan Z. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol Cell Biochem. 2012;369:27–33.CrossRefPubMed
21.
Yasuda J. Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 2003;308:227–33.CrossRefPubMed
22.
Dong JR. Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer. Asian Pac J Cancer Prev. 2013;14:7137–41.CrossRefPubMed
23.
Kohlhapp FJ. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015.
24.
25.
Chen Z. The pivotal role of microRNA-155 in the control of cancer. J Cell Physiol. 2014;229:545–50.CrossRefPubMed
26.
Ji J. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80.CrossRefPubMedPubMedCentral
27.
Wang K. miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol. 2013;15:578–88.CrossRefPubMedPubMedCentral
28.
Shen Q. MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer. Cancer Lett. 2014;344:204–11.CrossRefPubMed
29.
Zou D. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumour Biol. 2015.
30.
Xu ZY. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci. 2013;9:587–97.CrossRefPubMedPubMedCentral
31.
Yang F. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013;139:437–45.CrossRefPubMed
32.
Vernucci M. The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene. 2000;19:6376–85.CrossRefPubMed
33.
Du Y. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem. 2012;287:26302–11.CrossRefPubMedPubMedCentral
34.
35.
Martens-Uzunova ES. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140–51.CrossRefPubMed
36.
Zhang JX. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro Oncol. 2013;15:1595–603.CrossRefPubMedPubMedCentral
37.
Zhou X. HOTAIR is a therapeutic target in glioblastoma. Oncotarget. 2015.
38.
Takebe N. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97–106.CrossRefPubMed
39.
40.
Ishitani T. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23:1379–89.CrossRefPubMedPubMedCentral
41.
Yasuda J. Mammalian Nemo-like kinase enhances beta-catenin-TCF transcription activity in human osteosarcoma and neuroblastoma cells. Proc Jpn Acad Ser B Phys Biol Sci. 2007;83:16–25.CrossRefPubMedPubMedCentral
42.
43.
Bender TP. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol. 2004;5:721–9.CrossRefPubMed
Metadata
Title
The emerging role of Nemo-like kinase (NLK) in the regulation of cancers
Authors
Ying Huang
Yang Yang
Yong He
Jun Li
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4159-7

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines

Research Article

Influence of functional polymorphisms in TNF-α, IL-8, and IL-10 cytokine genes on mRNA expression levels and risk of gastric cancer

Research Article

Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein

Research Article

miR-141 as potential suppressor of β-catenin in breast cancer

Research Article

The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas

Research Article

Combination of miRNA and RNA functions as potential biomarkers for gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits